Contineum Therapeutics (CTNM) Accumulated Depreciation (2023 - 2024)
Contineum Therapeutics (CTNM) recorded quarterly Accumulated Depreciation of $1.7 million in Q4 2024, up 16.25% quarter-over-quarter from $1.5 million in Q4 2023, and up 16.25% on a YoY basis from $1.5 million in Q1 2024.
Contineum Therapeutics (CTNM) Accumulated Depreciation (2023 - 2024) Analysis & Trends
Contineum Therapeutics' Accumulated Depreciation history runs 2 years deep, the most recent figure standing at $1.7 million for Q4 2024.
- In Q4 2024, Accumulated Depreciation rose 16.25% year-over-year to $1.7 million; the TTM figure through Dec 2024 stood at $1.7 million (up 16.25% YoY), while the FY2024 annual figure was $1.7 million, up 16.25% from the prior year.
- Accumulated Depreciation was $1.7 million for Q4 2024 at Contineum Therapeutics, up from $1.5 million in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $1.7 million in Q4 2024 to a low of $1.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Contineum Therapeutics | 423.05 Mn | 423.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.72 Mn |
| Dec 31, 2023 | 1.48 Mn |